Onconostic Technologies-3N Diagnostics Group (OT/3NDx), an emerging leader in precision oncology diagnostics, today announced clinical validation of the pan-cancer, tissue agnostic utility of VERESCA based on detection of FOXC1 protein in oral cancer.
